Terns Pharmaceuticals | LinkedIn (original) (raw)

Biotechnology Research

Foster City, California 8,189 followers

Taking the Journey Towards Comprehensive Treatment of Serious Disease

View all 63 employees

About us

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline includes three clinical-stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist and preclinical GIPR modulator programs. For more information, please visit: www.ternspharma.com. Disclaimer: Reposts and posts of contents are for informational purposes only and do not constitute endorsements or promotions of any third-party products, services or organizations (including any statements, views or conducts by such organizations) unless explicitly stated otherwise.

Industry

Biotechnology Research

Company size

51-200 employees

Headquarters

Foster City, California

Type

Privately Held

Founded

2017

Specialties

Pharmaceuticals, Liver Disease, Life Sciences, and BioPharmaceuticals

Locations

Employees at Terns Pharmaceuticals

Updates

Today during #ESHCML2024, our team presented previously reported data on our proprietary allosteric BCR-ABL tyrosine kinase inhibitor (#TKI) for chronic myeloid leukemia (#CML) during two poster presentations. These findings mark an important step forward in our CML program, showcasing the potential of our allosteric BCR-ABL TKI as a promising alternative to standard active site inhibitors. To learn more, stop by our Terns booth in the exhibit hall throughout the conference! European School of Haematology (ESH) International CML Foundation
Attending ESH-#iCMLf 26th Annual John Goldman Conference on Chronic Myeloid Leukemia (#CML): Biology and Therapy (#ESHCML2024) this week? We’d love to meet you! Stop by the Meridian Room to explore our latest research Our team will present data from our CML development program during two poster presentations today at 6:50 pm CET. Meet us at the Terns Booth in the exhibit hall Stop by our booth during the conference! Chat with the team, learn more about the Phase 1 CARDINAL trial, and discuss how we're working to transform the landscape of CML treatment. European School of Haematology (ESH) International CML Foundation
#ICYMI: Last week, we shared positive top-line results from our Phase 1 clinical trial evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of our investigational oral GLP-1R agonist in healthy adults with #obesity or overweight. This milestone is a significant step forward in our clinical development program for metabolic disorders, and we’re excited to advance into Phase 2 in 2025. For more details, read the full release here: https://lnkd.in/e6VXMJ5U
Today is #WCMLD24, a global initiative by CML Advocates Network to raise awareness for chronic myeloid leukemia (#CML), a rare but important #bloodcancer that represents 10% of all leukemia cases. While CML often requires lifelong management, advances in research and treatment have allowed many patients to lead fulfilling lives. On this day, we stand in solidarity with the global CML community, highlighting the critical need for ongoing research, patient support, and advocacy. As part of our ongoing commitment, our team made blankets and wrote personalized notes to provide comfort and encouragement to those affected by blood cancers. We stand together on #WorldCMLDay! 🌍❤️ Learn more: https://lnkd.in/eHypqKC
September is Leukemia & Lymphoma Month. With chronic myeloid #leukemia being a lifelong chronic condition requiring ongoing management, our efforts at Terns are focused on developing innovative therapies that can make a meaningful difference in people's lives. We understand the challenges faced by those living with CML, and we are dedicated to advancing research and treatment options that offer hope and improve quality of life. Access to multiple lines of treatment is crucial for improving outcomes in #CML. Our Phase 1 CARDINAL trial, a global study evaluating the safety and potential efficacy of our proprietary allosteric BCR-ABL inhibitor, seeks to offer new options for individuals who may benefit from alternative treatments. Learn more: https://lnkd.in/d2cXYKC #BloodCancerAwarenessMonth
Last week during #SOHO2024, our team participated in a poster session where we presented two posters exploring data from our chronic myeloid leukemia (#CML) program, including previously reported data from the ongoing Phase 1 pharmacokinetic study of our allosteric BCR-ABL inhibitor. This study is a crucial step in understanding how our investigational therapy is metabolized in the body, and we're eager to continue advancing this research to better address the needs of patients living with CML. Thanks to all who visited during our session! Society of Hematologic Oncology
We are pleased to announce positive top-line data from a Phase 1 clinical trial assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of our oral GLP-1R agonist in healthy adults with #obesity or overweight. We believe these results underscore the potential of our investigational therapy to emerge as a class-leading #GLP1R agonist, and we're excited to advance into Phase 2 clinical development in 2025. See our press release for details: https://lnkd.in/e6VXMJ5U

Join now to see what you are missing

Join now

Terns Pharmaceuticals | LinkedIn (original) (raw)

Biotechnology Research

Foster City, California 8,189 followers

Taking the Journey Towards Comprehensive Treatment of Serious Disease

About us

Locations

Employees at Terns Pharmaceuticals

Updates

Join now to see what you are missing

Similar pages

Browse jobs

Funding